The present status of childhood cancer therapy in Korea.
We have studied the incidence pattern of childhood cancers in Korea. Although the incidence of many tumors in Korea is similar to that in other countries, the incidence of acute myelogenous leukemia, non-Hodgkin's lymphoma and hepatoma is greater in Korean children. Yonsei Cancer Center commenced a study of multi-modality treatment of childhood cancers in July 1974. The most striking improvement of survival rate was seen in patients with acute lymphocytic leukemia (50% at 5 years), Wilms' tumor (65% at 5 years), neuroblastoma (45% at 2 years), osteogenic sarcoma (55% at 2 years) and malignant histiocytosis (20% at 5 years). This study is an attempt to create a basic framework providing the best possible treatment of childhood cancer in Korea. The data obtained in Korea are briefly compared with those in Japan and the United States.
D000293:Adolescent; D000367:Age Factors; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D004812:Epidemiologic Methods; D005260:Female; D006801:Humans; D007223:Infant; D007564:Japan; D007723:Korea; D007945:Leukemia, Lymphoid / Q000628:therapy; D008206:Lymphatic Diseases / Q000628:therapy; D008297:Male; D009369:Neoplasms / Q000401:mortality / Q000628:therapy*; D012516:Osteosarcoma / Q000628:therapy; D012737:Sex Factors; D014481:United States; D009396:Wilms Tumor / Q000628:therapy